The FDA telehealth compounded drugs message is straightforward: telehealth itself is not the problem. Misleading advertising is. A site should say who prescribes the medicine, who compounds and dispenses it, and that a compounded preparation is not a generic or a brand-name product. It should never borrow a brand's review record as proof for a different preparation.
For someone considering online care, the simplest test is whether the page makes those differences easier to see or tries to blur them.
What the FDA telehealth compounded drugs page says
As of September 9, 2026, the day this article was written, FDA's page, content current June 15, 2026, warned telehealth companies about five kinds of false or misleading promotion involving compounded drugs. The reminder centers on GLP-1 medicines, drugs that copy gut-hormone signals involved in appetite and blood sugar, but it also refers to other compounded drugs.
Here is the plain-English version:
| Red flag | What FDA says is misleading | What a clear page says instead |
|---|---|---|
| The clinic looks like the maker | Branding on a vial or site can imply that the telehealth company compounded the drug when it did not | The site separates the telehealth service, prescriber, and dispensing pharmacy |
| The product is not honestly described | A compounded preparation is not a generic of Ozempic, Wegovy, Mounjaro, or Zepbound | It is described as a separate, compounded prescription |
| Agency review is implied | The specific compounded drug has not received FDA premarket review for safety, effectiveness, and quality | Its review status is stated plainly |
| Brand studies are treated as proof | Results from a brand product do not prove that a compounded preparation produces the same result | Evidence is tied to the exact product and formulation studied |
| The pharmacy is presented as agency-approved | No pharmacy is FDA-approved or FDA-licensed; FDA may register or inspect certain facilities, which is different | The pharmacy's actual state license or 503B registration is described accurately |
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
Why FDA issued the warning
This wasn't a theoretical concern. On March 3, 2026, FDA announced 30 warning letters over false or misleading claims about compounded GLP-1 products. The agency highlighted claims implying sameness with reviewed brand products and images that made a telehealth company's branding look like the compounder's identity.
Earlier research had found the same pattern. A 2025 JAMA Health Forum audit of 79 websites found that 11 did not disclose that the GLP-1 medicine was compounded, seven treated products as generic even though they were not, and 29 stated or implied that a drug had agency approval. Thirty-two advertised an effectiveness claim that was not in the relevant brand label.
Fresh research shows why clear online disclosures now matter to a lot of people. A JAMA research letter published July 6, 2026 reported that nearly 1 in 5 adults taking a GLP-1 medicine obtained a prescription online. The authors used a secret-shopper design, meaning a researcher posed as a patient, to examine the prescription process and clinical engagement. Advertising is only the front door; a real medical review has to be behind it.
What an honest telehealth page lets you verify
A reassuring page is specific, even when the answer is less tidy than a sales slogan. It identifies the licensed prescriber or explains how to verify that person's license. It names the dispensing pharmacy of record and gives enough information to check the pharmacy with its state board. It describes the product as compounded every time that distinction matters.
The roles should stay separate. A telehealth platform connects the patient and clinician. The clinician reviews the medical history and, when appropriate, writes a prescription. A licensed pharmacy compounds it, meaning it prepares the prescribed formulation, and dispenses it. A clinic logo on a vial can muddy that chain if the label does not make the actual compounder clear.
The medical review should also look like medicine, not a formality. Relevant history, current drugs, reasons the medicine may be unsafe, side effects, and follow-up all belong in the process. That is the practical difference between a prescription path and an anonymous vial.
For the product-specific distinction, compounded semaglutide in 2026 explains the separate questions around ingredient form, labeling, and post-shortage rules. The same disclosure test applies to compounded tirzepatide: a service should keep its prescriber and pharmacy roles clear and never present the preparation as Mounjaro or Zepbound.
What the FDA action does not mean
The warning is about promotional claims. It does not say that a video visit is required in every case, that every telehealth prescription is improper, or that one type of visit fits every patient. State licensure, the standard of care, the drug, and the patient's circumstances still shape the review.
It also does not turn registration into endorsement. A 503B outsourcing facility is a sterile-drug compounder that elects to register with FDA and meet added federal requirements. FDA's registry, updated September 8, 2026, can confirm registration; it does not mean the facility or every product it makes has agency approval. State boards remain central for pharmacy licensing.
FDA review status is one part of the picture: a licensed provider may still prescribe a compounded formulation when the clinical and legal conditions are met, and that decision is between the patient and the doctor.
The same checklist applies beyond GLP-1s
The June reminder focused on compounded GLP-1 advertising, but its basic honesty test travels well. A page for BPC-157 or another peptide should still identify the prescriber and pharmacy, avoid borrowing evidence from a different finished product, and state the product's actual regulatory status. Are peptides legal? explains why the prescription, ingredient, pharmacy, and state rules all matter; a broad label such as "peptide" does not settle the question.
What to watch next
FDA says it will keep watching promotional materials and may take further action over misleading claims. Warning letters are public and specific to the claims FDA reviewed; they are not a substitute for checking the current page, the prescriber's license, and the pharmacy record attached to an individual prescription.
The useful standard is simple: the more medical accountability a service claims, the easier that accountability should be to verify. At Promise, a licensed provider reviews every request, and not everyone qualifies.